A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428Phase 3Recruiting
- Lead sponsor
- Hutchmed (Industry)
- Enrollment
- 240 (estimated)
- Start date
- 20 Mar 2026
- Primary completion
- 30 Apr 2028 (estimated)
- Study completion
- 30 Dec 2028
- Last update posted
- 20 Jul 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- HMPL-760 Drug
- HMPL-760 Placebo Drug
- R-GemOx Drug
Conditions and primary outcome
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Primary outcome
Progression-free survival (PFS) (Up to approximately two years); End of treatment (EOT) (Up to approximately two years); Systemic antitumor therapy (Up to approximately two years); Overall survival (OS) (Up to approximately two years); systematic anti-tumor therapy (Up to approximately two years); Premature withdrawal from study treatment (Up to approximately two years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07409428.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07409428 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.